Scarica l'app Stockscreener
1.43
4.38%
0.06
Dopo l'orario di chiusura:
1.46
0.03
+2.10%
Ikena Oncology Inc Borsa (IKNA) Ultime notizie
Ikena Oncology shares fall 2.03% after-hours following acquisition by Inmagene Biopharmaceuticals. - AInvest
Ikena Oncology Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - MSN
Ikena Oncology Completes Merger with Inmagene Biopharmaceuticals - TipRanks
ImageneBio's Strategic Rebirth: A Catalyst for Long-Term Shareholder Value in the Atopic Dermatitis Market - AInvest
Inmagene Biopharmaceuticals Announces Completion of Merger - GlobeNewswire
Biotech Merger: Inmagene-Ikena Forms ImageneBio with $75M Backing from Elite Healthcare Investors - Stock Titan
What analysts say about Ikena Oncology Inc. stockHigh-impact stock picks - PrintWeekIndia
What drives Ikena Oncology Inc. stock priceExplosive trading opportunities - Autocar Professional
Ikena Oncology, Inc. SEC 10-Q Report - TradingView
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio - Investing.com Nigeria
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio By Investing.com - Investing.com South Africa
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Kristin Yarema to lead merged Inmagene-Ikena entity - biocentury.com
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company - Investing.com India
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - The Manila Times
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm By Investing.com - Investing.com South Africa
Roche-Acquired Poseida CEO Takes Helm at Ikena-Inmagene Merger with $75M Funding - Stock Titan
Ikena Oncology Announces Merger with Inmagene - TipRanks
IKNA issues special CVR dividend ahead of Inmagene merger | IKNA SEC FilingForm 8-K - Stock Titan
Is Ikena Oncology Inc. a good long term investmentBreakthrough stock performance - jammulinksnews.com
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting - Investing.com Nigeria
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting By Investing.com - Investing.com South Africa
Ikena Oncology Updates Employment Terms Amid Merger Plans - TipRanks
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewswire
How Ikena Oncology Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Ikena Oncology announces stockholder approval of merger with Inmagene Biopharmaceuticals - MarketScreener
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com Australia
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com Nigeria
Ikena Oncology Approves Merger with Inmagene Biopharmaceuticals - AInvest
Ikena Oncology Shareholders Green Light Inmagene Merger: What the 1-for-12 Split Means for Investors - Stock Titan
Why Ikena Oncology Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):